Molecularly targeted therapies for nonmelanoma skin cancers
Article first published online: 17 MAY 2013
© 2013 The International Society of Dermatology
International Journal of Dermatology
Volume 52, Issue 6, pages 654–665, June 2013
How to Cite
Liu, L. S. and Colegio, O. R. (2013), Molecularly targeted therapies for nonmelanoma skin cancers. International Journal of Dermatology, 52: 654–665. doi: 10.1111/ijd.12017
Conflicts of interest: No conflicts of interest for Dr. Colegio or Lucinda.
- Issue published online: 17 MAY 2013
- Article first published online: 17 MAY 2013
Over the past two decades, advances in the fields of cancer genetics and molecular biology have elucidated molecular pathways that cause numerous cutaneous malignancies. This in turn has spurred the rational design of molecularly targeted therapies. In this review, we discuss the molecular pathways critical to the development of nonmelanoma skin cancers and the novel pharmacologic agents that target them. Included is a review of vismodegib for basal cell carcinoma, cetuximab for squamous cell carcinomas, imatinib for dermatofibrosarcoma protuberans, and sirolimus for Kaposi's sarcoma.